Lord, Abbett & Co. LLC Ascendis Pharma A/S Transaction History
Lord, Abbett & Co. LLC
- $33.6 Billion
- Q3 2025
A detailed history of Lord, Abbett & Co. LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 151,427 shares of ASND stock, worth $31 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
151,427
Previous 154,176
1.78%
Holding current value
$31 Million
Previous $26.6 Million
13.13%
% of portfolio
0.09%
Previous 0.09%
Shares
7 transactions
Others Institutions Holding ASND
# of Institutions
318Shares Held
65MCall Options Held
476KPut Options Held
142K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion35.1% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...